

SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced that the company will participate at the BioEurope meeting on November 3-4, 2025, in Vienna, Austria. This is a premier event with more than 5.700 delegates representing pharma, biotech, and investors.

"BioEurope is one of the biggest platforms of the year for engaging with potential partners, and we are excited to engage in discussion on SynAct's progress and path forward. Our lead program, Resomelagon, is a potential first-in-class non-suppressive immune modulation therapy that we are developing for rheumatoid arthritis and for host directed inflammation due to viral infections. Both applications have the potential of supporting millions of patients on an annual basis. We look forward to discussions with companies at BioEurope on potential collaborations," said Mads Bjerregaard, Chief Business Officer of SynAct Pharma.

Thomas Jonassen, Chief Science Officer and founder, and Mads Bjerregaard, Chief Business Officer, will be attending the meeting.

BioEurope® 2025 is the premier event for life science with delegates from biotech, medtech, finance and research sectors. Over 5.700 delegates from more than 60 countries join a valuable program and over 30.000 partnering meetings is held over three days.

For further information, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

Attachments

[SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025](#)